Post by Rothschild & Co

We’re pleased to be hosting the 2026 Rothschild & Co Redburn Radiopharma Conference on Wednesday 27 May at The Langham Hotel in New York. Radiopharma continues to be one of the fastest-evolving areas in healthcare, with 2026 expected to bring further commercial RLT launches on validated approaches, alongside growing clinical efforts across emerging isotopes and biotargets. This year’s conference will bring together stakeholders from across the full radiopharma value chain, including large pharmaceutical companies, innovative biotechs, isotopes manufacturers, and investors for discussions examining key trends in radiopharma across drug pipeline and supply chain. It will also provide unique networking opportunities with industry executives and investors. We look forward to the panel discussions and company presentations with Jack Hoppin (Ratio Therapeutics), Germo Gericke (3B Pharmaceuticals GmbH), Gang C. (RadAlliance Therapeutics Inc), Jeevan Virk (Sego Therapeutics), Christian Behrenbruch (Telix Pharmaceuticals Limited), Etienne Montagut (PharmaLogic), and Nick Burley (Alliance Medical UK), and to connecting with many of you in New York. #GlobalAdvisory #Radiopharma #NuclearMedicine #Oncology